Vanguard Global Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.58M Buy
54,415
+6,564
+14% +$174K ﹤0.01% 1409
2026
Q2
$859K Hold
47,851
– – ﹤0.01% 1832
2026
Q1
$665K Buy
+47,851
New +$673K ﹤0.01% 1898

Other funds holding AMLX

Vanguard Global Advisers's AMLX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q3 2026, buying an estimated $174K and bringing the position to 54,415 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Vanguard Global Advisers first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 229 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Vanguard Global Advisers held 54,415 shares of Amylyx Pharmaceuticals worth $1.58M as of Q3 2026.
  • Vanguard Global Advisers bought 6,564 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $174K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1409 holding.
  • Vanguard Global Advisers first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 229 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.